Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Research & Development (2023 - 2025)

Kairos Pharma filings provide 2 years of Research & Development readings, the most recent being $496000.0 for Q2 2025.

  • On a quarterly basis, Research & Development rose 687.3% to $496000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $1.2 million, a N/A change, with the full-year FY2025 number at $2.1 million, up 415.7% from a year prior.
  • Research & Development hit $496000.0 in Q2 2025 for Kairos Pharma, up from $493000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $496000.0 in Q2 2025 to a low of $14000.0 in Q3 2024.